Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best biotech stocks to invest in now. On June 12, Syndax Pharmaceuticals announced that data from the BEAT AML trial involving revumenib were published in the Journal of Clinical Oncology and simultaneously presented at the 30th European Hematology Association/EHA Annual Congress Meeting, which was held from June 12-15 in Milan, Italy, and virtually.

The data showcased revumenib in combination with venetoclax and azacitidine (ven/aza) for newly diagnosed mutant NPM1 (mNPM1) and KMT2A-rearranged (KMT2Ar) acute myeloid leukemia/AML patients. The BEAT AML Phase 1b trial was part of The Leukemia & Lymphoma Society’s Beat AML Master Clinical Trial (NCT03013998) and evaluated the safety and clinical activity of this combination in newly diagnosed older adults (aged ≥60 years) with mNPM1 or KMT2Ar AML.

Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial

A scientist in a laboratory testing a monoclonal antibody for the treatment of cancer.

Revuforj (revumenib) is an oral, first-in-class, selective menin inhibitor that is FDA-approved for relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients aged one year and older. Revumenib is also in development for R/R AML with a nucleophosmin 1 mutation (mNPM1). Positive pivotal data from the AUGMENT-101 trial for this indication were recently published, and Syndax completed the submission of a supplemental New Drug Application (sNDA) for revumenib in R/R mNPM1 AML in April 2025.

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is a commercial-stage biopharmaceutical company that develops therapies for the treatment of cancer.

While we acknowledge the potential of SNDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.